Idioma:

Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers

Lai, Tiffany S ; Francoeur, Alex ; Manrriquez, Erica ; Venkat, Puja ; Chang, Albert ; Douek, Michael ; Bahrami, Simin ; Raman, Steven S ; Memarzadeh, Sanaz

Brachytherapy, 2024-05, Vol.23 (3), p.266-273 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por

Enviar para

Título:
Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers
Autor: Lai, Tiffany S ; Francoeur, Alex ; Manrriquez, Erica ; Venkat, Puja ; Chang, Albert ; Douek, Michael ; Bahrami, Simin ; Raman, Steven S ; Memarzadeh, Sanaz
Assuntos: Ablation Techniques ; Adult ; Aged ; Aged, 80 and over ; Brachytherapy - methods ; Female ; Genital Neoplasms, Female - radiotherapy ; Humans ; Middle Aged ; Neoplasm Metastasis - radiotherapy ; Neoplasm Recurrence, Local - radiotherapy ; Retrospective Studies ; Tomography, X-Ray Computed ; Treatment Outcome ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - radiotherapy ; Uterine Neoplasms - radiotherapy
É parte de: Brachytherapy, 2024-05, Vol.23 (3), p.266-273
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Treatment of recurrent oligometastatic gynecologic malignancy may involve targeted surgery, thermal ablation, or CT-guided high-dose-rate interstitial brachytherapy ablation (CT-HDR-IBTA). The purpose of this study was to describe the safety and efficacy of CT-HDR-IBTA for oligometastatic gynecologic malignancies. With institutional review board approval (IRB) approval and compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliance, we searched our database to assemble a single-arm study cohort of all patients with oligometastatic gynecologic cancers who underwent CT-HDR-IBTA from 2012-2022 with follow-up. The electronic record was reviewed to determine relevant clinicopathological variables including patient demographics, prior treatments, clinical course, local control, and local and distant recurrence with follow-up imaging. The study cohort comprised 37 lesions in 34 patients treated with CT-HDR-IBTA for recurrent oligometastatic uterine (n = 17), cervix (n = 1), or ovarian cancer (n = 16) with an average lesion size of 2.5 cm with an average patient age of 61.4 years. Each lesion was treated with an average radiation dose of 23.8 Gy in 1.8 fractions and a median follow-up time of 24.0 months. The primary efficacy of CT HDR ITBA was 73% with a median progression-free survival of 8.0 months (95% CI 3.6-12.8 months) and with 58% of patients still alive at 43 months with median overall survival not reached. The rate of Grade 1 adverse events was 22% without any Grade 2, 3 or 4 events. CT HDR IBTA was safe and effective for treating oligometastatic gynecologic cancers in a heavily pretreated cohort.
Editor: United States
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 9 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers

Lai, Tiffany S ; Francoeur, Alex ; Manrriquez, Erica ; Venkat, Puja ; Chang, Albert ; Douek, Michael ; Bahrami, Simin ; Raman, Steven S ; Memarzadeh, Sanaz

United States

Buscando em bases de dados remotas. Favor aguardar.